PRIMARY STUDY

Novel selective agonist of GPR18, PSB-KK-1415 exerts potent anti-inflammatory and anti-nociceptive activities in animal models of intestinal inflammation and inflammatory pain

Key Findings:  Resulting data suggests that modulation of GPR18 (via agonist PSB-KK-1415 and antagonist PSB-CB5) is worth considering as a potential treatment target in intestinal inflammation and inflammatory pain.